蛋白质组学和生物信息学识别了与药物耐药性相关的基因,这些基因在胆管癌中具有预后潜力
Kankamol Kerdkumthong1, Sittiruk Roytrakul2, Kawinnath Songsurin1
1Department of Biochemistry, Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai District, Songkhla 90110, Thailand.
Biomolecules
|August 29, 2024
概括
胆管癌 (CCA) 的耐药性涉及与细胞迁移和侵入相关的蛋白质. 针对这些蛋白质,如MET和LAMB1,可以克服耐药性并改善CCA患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 药物耐药性在治疗晚期胆管癌 (CCA) 方面构成了重大挑战.
- 确定耐药性机制对于发现新的生物标志物和治疗点至关重要.
- 了解这些机制可以提高CCA患者的治疗疗效.
研究的目的:
- 研究CCA中5-甲 (5-FU) 和gemcitabine耐药性的分子机制.
- 通过比较蛋白质组学来识别耐性CCA细胞中差异表达的蛋白质.
- 探索已识别的蛋白质的临床意义和治疗潜力.
主要方法:
- 已建立的抗5-FU (KKU-213FR) 和抗凝素 (KKU-213GR) 的CCA细胞系.
- 利用比较蛋白质组学来分析耐药细胞和亲细胞之间的蛋白质表达差异.
- 进行生物信息学分析,包括蛋白质-蛋白质相互作用和基因淘汰研究 (siRNA).
主要成果:
- 在KKU-213FR和KKU-213GR细胞中确认了耐药表型和增加的迁移/入侵.
- 确定了81种不同表达的蛋白质,与结合,调节和新陈代谢有关.
- 蛋白质与蛋白质相互作用网络突出显示了一些关键蛋白质 (MET,LAMB1,ITGA3,NOTCH2,CDH2,NDRG1).
- 这些基因的siRNA淘汰减少了迁移/入侵,并使细胞对化疗重新敏感.
- 在CCA患者中,这些基因的上调mRNA表达与预后不佳相关.
结论:
- 确定了关键的蛋白质和途径,包括表皮-介质酶转换 (EMT),参与CCA耐药性.
- 证明向特定蛋白质可以克服耐药性并减少瘤的进展.
- 这些发现为改善CCA治疗策略提供了潜在的治疗目标.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


